Verana Health Expands Site Explorer to Urology, Aims to Speed Clinical Trials
Event summary
- Verana Health updated its Site Explorer tool to include urology practice data alongside existing ophthalmology data on January 15, 2026.
- The tool now provides insights into both urology and ophthalmology trials, including practice-level details and anonymized patient demographics.
- Verana Health leverages exclusive partnerships with IRIS® and AQUA® registries, accessing de-identified data from over 90 million patients and 20,000 clinicians.
- The update aims to help trial sponsors and CROs reduce recruitment timelines and build more representative enrollment cohorts.
The big picture
Verana Health's expansion into urology with its Site Explorer tool reflects the growing trend of leveraging real-world data to enhance clinical trial efficiency. By integrating data from both ophthalmology and urology practices, Verana Health aims to address long-standing challenges in trial recruitment and site selection, potentially reducing costs and accelerating drug development timelines. The company's exclusive partnerships with major medical associations position it as a key player in the digital health space, where data-driven insights are increasingly critical for both clinical research and patient care.
What we're watching
- Data Utilization
- How Verana Health's expanded real-world data access will impact the speed and accuracy of clinical trial site selection.
- Market Differentiation
- Whether Verana Health can sustain its competitive edge with exclusive access to large-scale patient registries.
- Regulatory Compliance
- The pace at which regulatory frameworks adapt to the use of real-world data in clinical trials.